Expression of the tyrosine kinase c‐kit is an independent prognostic factor in patients with small cell lung cancer
Open Access
- 12 April 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 111 (2) , 259-263
- https://doi.org/10.1002/ijc.20252
Abstract
In a retrospective analysis of 203 patients with small cell lung cancer (SCLC), we examined the prognostic value of c‐kit expression on survival. Expression of c‐kit was examined immunohistochemically in formalin‐fixed, paraffin‐embedded tissue sections. c‐kit was observed in 87.7% of SCLC tumors. Using the Kaplan‐Meier model, we found that lack of c‐kit expression was associated with significantly shorter survival time compared to the presence of c‐kit expression (mean survival 151 ± 27 vs. 358 ± 49 days, p = 0.0084). Moreover, the proportion of c‐kit+ cells within the tumor was also related to survival time. Patients with tumors in which >75% of cells stained positive for c‐kit had a mean overall survival time of 424 (±72) compared to 295 (±67) days for patients with 25–75% c‐kit+ tumor cells. Patients with tumors containing + cells had the worst survival, with 164 (±24) days (p = 0.0033). Further parameters associated with short survival times were low performance status, elevated levels of lactate dehydrogenase and higher stage according to the TNM classification. Multivariate analysis using the Cox regression model showed that the proportion of c‐kit+ cells within the tumor specimen was one of 3 independent prognostic parameters (p = 0.004) for overall survival next to TNM classification (p = 0.001) and performance status (p < 0.001).Keywords
Funding Information
- Leukämie Liga
- Novartis Inc.
This publication has 12 references indexed in Scilit:
- CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinomaAnnals of Oncology, 2003
- Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosisHuman Pathology, 2002
- Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterationsHuman Pathology, 2002
- Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571Oncogene, 2000
- The international system for staging lung cancerSeminars in Surgical Oncology, 2000
- Mutations in Exon 11 of c-Kit Occur Preferentially in Malignant versus Benign Gastrointestinal Stromal Tumors and Do Not Occur in Leiomyomas or LeiomyosarcomasThe American Journal of Pathology, 1999
- Specific Growth Inhibition of Small‐cell Lung Cancer Cells by Adenovirus Vector Expressing Antisense c‐kit TranscriptsJapanese Journal of Cancer Research, 1996
- Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell linesEuropean Journal Of Cancer, 1995
- Ectopic expression of c-kit in small-cell lung cancerInternational Journal of Cancer, 1994
- Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenograftsBritish Journal of Cancer, 1993